JavaScript seems to be disabled in your browser. You must have JavaScript enabled in your browser to utilize the functionality of this website.
Description: Febuxostat (formerly also called TMX 67, TEI-6720; TEI 6720; Uloric; TMX-67) is a potent and selective xanthine oxidase inhibitor with Ki of 0.6 nM and has been used to treat hyperuricemia and chronic gout. Febuxostat displayed potent mixed-type inhibition of the activity of xanthine oxidase (XO). Febuxostat was also reported to be 1000-fold (IC50=1.8 nM) more potent than allopurinol (IC50= 2.9 uM) at inhibiting XO-dependent uric acid formation. In a previous study, the authors investigated the effects of febuxostat on several enzymes in purine and pyrimidine metabolism and characterized the mechanism of febuxostat inhibition of XO activity. Results showed that Febuxostat displayed potent mixed-type inhibition of the activity of purified bovine milk XO, indicating inhibition of both the oxidized and reduced forms of XO.
References: Life Sci. 2005 Mar 4; 76(16):1835-47. Epub 2005 Jan 18; Am J Physiol Renal Physiol. 2008 Apr; 294(4):F710-8; Nephron Physiol. 2008; 108(4):p69-78.
Related CAS#: 1246819-50-0 (Febuxostat D9 is deuterium labeled Febuxostat)
Note: The presented information and documents (Manual, Product Datasheet, Safety Datasheet and Certificate of Analysis) correspond to our latest update and should serve for orientational purpose only. We do not guarantee the topicality. We would kindly ask you to make a request for specific requirements, if necessary.
All products are intended for research use only (RUO). Not for human, veterinary or therapeutic use.
Request Data Sheet
Request product datasheet
Request safety datasheet
Delivery expected until 9/4/2025
Compare
Add to wishlist
Get an offer
Request delivery time
Ask a technical question
Submit a bulk request
sales@hoelzel.de
« Back
Subscribe, get 15% off every fifth order and have your items delivered on time!
Forgot Your Password?
Not yet registered? Create account here!